Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | ADCY10 | Q96PN6 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KCNK3 | O14649 | 9/20 | 0.38 |
| ▸ | KCNK9 | Q9NPC2 | 9/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14764960 | 0.79 | KDM4E (0.49) | KDM4EDPP4NPC1RAB9AHTT | |
| SCHEMBL14763696 | 0.79 | RAB9A (0.49) | KDM4EDPP4ADCY10NPC1RAB9A | |
| SCHEMBL1691209 | 0.75 | DPP4 (0.77) | KDM4EDPP4NPC1RAB9APOLB | |
| SCHEMBL859067 | 0.73 | KDM4E (1.00) | KDM4EDPP4NPC1RAB9APOLB | |
| SCHEMBL1691661 | 0.71 | KDM4E (0.69) | KDM4ENPC1RAB9APOLBHTT | |
| SCHEMBL13470777 | 0.71 | KDM4E (0.55) | KDM4EDPP4ADCY10NPC1RAB9A | |
| SCHEMBL14772071 | 0.68 | MAPT (0.39) | KDM4ENPC1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL221416 | 0.67 | KDM4E (0.49) | KDM4EDPP4NPC1RAB9APOLB | |
| SCHEMBL1691474 | 0.66 | ALDH1A1 (0.58) | KDM4ENPC1RAB9APOLBHTT | |
| SCHEMBL1691506 | 0.66 | ALDH1A1 (0.58) | KDM4ENPC1RAB9APOLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2753325-B1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2018-09-19 | — | — | EP | disclosed |
| US-9265773-B2 | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9265773-B2 | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9265773-B2 | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20140213571-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2014-07-31 | — | — | US | disclosed |
| WO-2013033971-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013033971-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213571-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | HCCS, HAVCR2, EIF2AK2 | KDM4E 3597/4885DPP4 1994/4885ADCY10 4485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.